Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer To Acquire Urology Agent Fesoterodine From Schwarz

This article was originally published in The Pink Sheet Daily

Executive Summary

The deal also ends a patent dispute regarding fesoterodine and Pfizer's incontinence agent Detrol.

You may also be interested in...



Pfizer Toviaz Clears FDA For OAB: Three-Year Window To Establish Detrol Successor

Anti-muscarinic agent acquired from Schwarz in 2006 to hit U.S. market in 2009; in time to build sales before Pfizer’s Detrol goes off-patent in 2012.

Pfizer Toviaz Clears FDA For OAB: Three-Year Window To Establish Detrol Successor

Anti-muscarinic agent acquired from Schwarz in 2006 to hit U.S. market in 2009; in time to build sales before Pfizer’s Detrol goes off-patent in 2012.

Pfizer Blames Fesoterodine Partner Schwarz For Launch Delay

The company anticipates the incontinence therapy will launch in early 2009, nearly two years later than expected.

Related Content

Topics

UsernamePublicRestriction

Register

PS063998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel